Skip to main content
. Author manuscript; available in PMC: 2019 Feb 8.
Published in final edited form as: Sci Transl Med. 2017 Jan 11;9(372):eaai8269. doi: 10.1126/scitranslmed.aai8269

Fig. 3. Combined inhibition of Aurora kinase A and JAK2 enhances antigen-specific iTreg-suppressive potency.

Fig. 3

(A) Bar graph depicts mean % demethylation of Foxp3 ± SEM among iTregs in alloMLRs treated with AJI-214 (750 nM) or DMSO from four independent experiments using triplicate technical replicates. (B) The suppressive capacity of sorted, DC-allostimulated iTregs previously exposed to AJI-214 or DMSO was tested at different ratios of iTreg to T cell responders stimulated by fresh allogeneic DCs (DC/responder T cell ratio of 1:30) in alloMLRs. No additional AJI-214 or DMSO was added. Bar graph shows means of % proliferation ± SEM based on [3H]thymidine incorporation on day 6 from three independent experiments with triplicate technical replicates (ANOVA). (C) The potency of iTregs generated in the presence of alisertib (1.75 μM), TG101348 (350 nM), a combination of alisertib and TG101348, or DMSO was tested in standard suppression assays. No additional small-molecule inhibitors or DMSO was added. Bar graph shows means of % proliferation ± SD based on [3H]thymidine incorporation on day 6 (paired t test). Data are from one representative experiment of two performed using triplicate technical replicates. *P < 0.05.